---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-000431"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:37:43.697096+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints Rogério Vivaldi Coelho, M.D., M.B.A. to board of directors

## Summary
- Board increased from 6 to 7 members; Vivaldi appointed to Class I director, term expiring at 2022 annual meeting.
- Vivaldi also appointed to Audit Committee; receives annual cash retainer of $40,000 plus $7,500 for committee service.
- Granted option to purchase 25,000 shares vesting over three years in equal annual installments.
- Vivaldi brings over 20 years of rare disease pharma experience, including CEO of Sigilon Therapeutics and prior roles at Bioverativ, Spark, and Genzyme.

## SEC filing metadata
- accession: 0001564590-22-000431
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000156459022000431/0001564590-22-000431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000156459022000431/crnx-8k_20220103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-000431
- JSON: https://secwatch.observer/filing/0001564590-22-000431.json
- Plain text: https://secwatch.observer/filing/0001564590-22-000431.txt

## Key facts
- Executive change
  Rogério Vivaldi Coelho was appointed as Class I Director at Crinetics Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: the Board approved an increase in its authorized size from six members to seven members and appointed Rogério Vivaldi Coelho, M.D., M.B.A. to fill the vacancy created by such increase and serve as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000156459022000431/0001564590-22-000431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.